A New Oral Medicine for Visceral Leishmaniasis
Orally available NOD2 agonist, HPX-612, for the treatment of visceral leishmaniasis
['FUNDING_SBIR_1'] · TRAVERSE BIOTECH II INC · NIH-11081016
This project is developing a new oral medicine called HPX-612 to help people with visceral leishmaniasis, a parasitic disease.
Quick facts
| Phase | ['FUNDING_SBIR_1'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | TRAVERSE BIOTECH II INC (nih funded) |
| Locations | 1 site (New York, UNITED STATES) |
| Trial ID | NIH-11081016 on ClinicalTrials.gov |
What this research studies
Visceral leishmaniasis affects millions globally, and current treatments often involve painful injections with severe side effects and limited access in remote areas. This new medicine, HPX-612, is designed to be taken by mouth, making it much easier for patients. It works by boosting the body's natural defenses, specifically targeting a protein called NOD2, which helps immune cells fight off the Leishmania parasite. By activating this natural immune response, HPX-612 aims to clear the infection more effectively and safely.
Who could benefit from this research
Good fit: This research is focused on developing a new treatment for individuals diagnosed with visceral leishmaniasis.
Not a fit: Patients who do not have visceral leishmaniasis would not directly benefit from this specific treatment.
Why it matters
Potential benefit: If successful, this new oral medicine could offer a more accessible, less painful, and potentially more effective way to treat visceral leishmaniasis, especially for those in remote regions.
How similar studies have performed: While HPX-612 is a novel product, previous research has shown that activating the NOD2 protein can help the body fight Leishmania parasites.
Where this research is happening
New York, UNITED STATES
- TRAVERSE BIOTECH II INC — New York, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: ROMET-LEMONNE, JEAN-LOUP — TRAVERSE BIOTECH II INC
- Study coordinator: ROMET-LEMONNE, JEAN-LOUP
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.